

# Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

## Update regarding the thiazolidinediones

D. M. Nathan · J. B. Buse · M. B. Davidson ·  
E. Ferrannini · R. R. Holman · R. Sherwin · B. Zinman

Published online: 12 January 2008  
© Springer-Verlag 2007

Unfortunately some errors appeared in this paper.

In Table 1, ‘Potential decrease MI<sup>b</sup>’ should have appeared as an Advantage, not Disadvantage, for Thiazolidinediones (glitazones).

In Figure 1, the footnote for ‘Intensive insulin + metformin ± glitazone’ should have been <sup>b</sup> not <sup>c</sup>.

In the Discussion, the sentence: ‘These findings have led to a stronger (black box) warning in the prescribing

information for the thiazolidinediones [15]’ should have read:

‘These findings have led to a stronger ‘black box’ warning in the prescribing information for rosiglitazone regarding the risk for myocardial infarction and for both thiazolidinediones regarding the risk for CHF [15]’.

Reference 15: The website was last accessed on 17 November 2007, not 25 October 2007.

---

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00125-007-0873-z>.

---

D. M. Nathan (✉)  
Diabetes Center, Massachusetts General Hospital,  
Harvard Medical School,  
Boston, MA 02114, USA  
e-mail: [dnathan@partners.org](mailto:dnathan@partners.org)

J. B. Buse  
University of North Carolina School of Medicine,  
Chapel Hill, NC, USA

M. B. Davidson  
Charles R. Drew University,  
Los Angeles, CA, USA

E. Ferrannini  
Department of Internal Medicine, University of Pisa,  
Pisa, Italy

R. R. Holman  
Diabetes Trials Unit, Oxford Centre for Diabetes,  
Endocrinology and Metabolism, Oxford University,  
Oxford, UK

R. Sherwin  
Yale University School of Medicine,  
New Haven, CT, USA

B. Zinman  
Samuel Lunenfeld Research Institute, Mount Sinai Hospital,  
University of Toronto,  
Toronto, ON, Canada